Collaboration and Licensing Revenue (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the years ended December 31, 2022, 2021, and 2020.

	Year Ended December 31,
	2022		2021		2020
Alaunos Therapeutics, Inc.	$	100	$	100	$	200
Oragenics, Inc.	—		—		3,053
Intrexon Energy Partners, LLC	3,768		—		—
Intrexon Energy Partners II, LLC	10,793		—		—
Castle Creek Biosciences, Inc.	—		388		17,810
Other	—		18		145
Total (1)	$	14,661	$	506	$	21,208

(1)Collaboration and licensing revenues recognized for the years ended December 31, 2022, 2021, and 2020, include the recognition of $14,561, $397, and $20,205, respectively, associated with upfront and milestone payments which were previously deferred.

Summary of Deferred Revenue

Deferred revenue consisted of the following:

	December 31,
	2022		2021
Collaboration and licensing agreements	$	1,818	$	23,023
Prepaid product and service revenues	15		1,277
Other	10		213
Total	$	1,843	$	24,513
Current portion of deferred revenue	$	25	$	1,490
Long-term portion of deferred revenue	1,818		23,023
Total	$	1,843	$	24,513

Summary of Deferred Revenue by Collaborator